One-on-one with medical innovators
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness that in many ways go against mainstream theories about obesity.
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the market’s new realities.
James Lanthier, the CEO of Mindset Pharma Inc., talks about developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.
Extending the Human Lifespan, a BioWorld special report, examines the companies developing “Fountain of Youth” drugs. In this episode, the writers discuss this scientific holy grail.
Executives from Amylyx Pharmaceuticals Inc. and Clene Inc., along with a key Penn State ALS expert, discuss what the future of medicine holds for patients.